focus -WSS

focus

author：comprehensive 2025-09-05 08:03:31 - browse：2577

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Divers poised to search for children washed away in Pennsylvania flash flood

hotspot

WSS

A preacher's new calling: Diversifying neuroscience research

Physician assistants need a new name. Here's what it should be

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Arena BioWorks launches in Cambridge to speed drug discovery

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

entertainment

focus

leisure time

Virginia high school admissions case could be legal follow

DeSantis talks Trump, trans issues and 'what wokeness is'

BioMarin wins approval for gene therapy to treat hemophilia A

Ending racial health disparities hinges on penalties, political will

Tori Bowie and the unacceptable rates of Black maternal death

Boston Scientific acquires urology company Axonics for $3.7 billion

At least 13 dead in Texas as scorching temps continue

Physician assistants need a new name. Here's what it should be

Drug repurposing or repositioning? The language matters

Driven by the pandemic, applicants flood public health schools

explore

Tocagen's brain cancer gene therapy trial continues. Investors worry

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Does Paxlovid work in people vaccinated against Covid

EF3 tornado rips through North Carolina amid extreme weather nationwide

Merck to acquire Harpoon Therapeutics for $680 million

Profiling embryos to choose those with higher IQs is almost a reality

explore

focus

hotspot

Wikipedia